The new approval will help Merck make a return on its $3.9 billion investment in acquiring SpringWorks, which has operated as ...

"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...

Sarepta has refused to suspend all dosing of its gene therapy for Duchenne muscular dystrophy, Elevidys, defying a clinical ...